Special Report
Rahul Mehan, MD, and Nick Liu, MD, discuss the June 2025 US Food and Drug Administration approval of mitomycin (Zusduri), formerly known as UGN-102, for for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
3
Published data show benefit of niraparib with AAP in HRR-deficient mCSPC
4
Integrating chemoablation into everyday NMIBC practice
5
